Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF) (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $608000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 25.1% to $608000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 157.08% increase, with the full-year FY2025 number at $3.0 million, up 157.08% from a year prior.
  • Depreciation & Amortization (CF) was $608000.0 for Q4 2025 at Cartesian Therapeutics, roughly flat from $606000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q1 2025 to a low of $176000.0 in Q2 2023.
  • A 5-year average of $374600.0 and a median of $322000.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 48.99% in 2023, then skyrocketed 531.69% in 2025.
  • Cartesian Therapeutics' Depreciation & Amortization (CF) stood at $401000.0 in 2021, then crashed by 39.9% to $241000.0 in 2022, then rose by 12.86% to $272000.0 in 2023, then surged by 78.68% to $486000.0 in 2024, then rose by 25.1% to $608000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Depreciation & Amortization (CF) are $608000.0 (Q4 2025), $606000.0 (Q3 2025), and $589000.0 (Q2 2025).